Annual report pursuant to Section 13 and 15(d)

Schedule of Identifiable Intangible Assets Carrying Value (Details)

v3.24.1
Schedule of Identifiable Intangible Assets Carrying Value (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]    
Total $ 31,951 $ 31,951
Accumulated Amortization (31,951) (31,090)
Net Carrying Value 861
CLIA Lab [Member]    
Finite-Lived Intangible Assets [Line Items]    
Total $ 609 609
Finite lived intangible asset, useful life 2 years 3 months 18 days  
Asuragen Acquisition [Member] | Thyroid [Member]    
Finite-Lived Intangible Assets [Line Items]    
Total $ 8,519 8,519
Finite lived intangible asset, useful life 9 years  
Red Path Acquisition [Member] | Pancreas Test [Member]    
Finite-Lived Intangible Assets [Line Items]    
Total $ 16,141 16,141
Finite lived intangible asset, useful life 7 years  
Red Path Acquisition [Member] | Barretts Test [Member]    
Finite-Lived Intangible Assets [Line Items]    
Total $ 6,682 $ 6,682
Finite lived intangible asset, useful life 9 years